Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Worldwide Offices
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Hereditary Transthyretin Amyloidosis Market Forecasts Strong Growth Amid New Treatment Launches | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

08 Oct, 2025, 21:31 GMT

Share this article

Share toX

Share this article

Share toX

The hereditary transthyretin amyloidosis market is experiencing significant growth driven by increasing disease awareness, advancements in gene-silencing therapies, and the rising prevalence of the condition globally. The market is further fueled by emerging therapies such as Nexiguran ziclumeran (Intellia Therapeutics), ALXN2220 (Neurimmune/Alexion Pharmaceuticals), Coramitug (Novo Nordisk), and others.

LAS VEGAS, Oct. 8, 2025 /PRNewswire/ -- DelveInsight's Hereditary Transthyretin Amyloidosis Market Insights report includes a comprehensive understanding of current treatment practices, hereditary transthyretin amyloidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Hereditary Transthyretin Amyloidosis Market Summary

  • The market size for hereditary transthyretin amyloidosis in the leading markets is expected to grow significantly by 2034.
  • The United States accounted for the highest hereditary transthyretin amyloidosis treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
  • The US accounted for nearly 65% of the total diagnosed prevalent cases of hATTR in the 7MM in 2024, which is expected to increase further by 2034.
  • Leading hereditary transthyretin amyloidosis companies developing emerging therapies, such as Intellia Therapeutics, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, and others, are developing new therapy for hereditary transthyretin amyloidosis that can be available in the hereditary transthyretin amyloidosis market in the coming years. 
  • The promising hereditary transthyretin amyloidosis therapies in clinical trials include Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, and others.

Discover the hereditary transthyretin amyloidosis new treatment @ New Treatments for Hereditary Transthyretin Amyloidosis

Key Factors Driving the Growth of the Hereditary Transthyretin Amyloidosis Market 

Advancements in Genetic Testing and Early Diagnosis

Improved genetic testing techniques have enhanced the ability to diagnose hATTR at earlier stages. This advancement enables timely interventions, resulting in improved patient outcomes and increased demand for specialized treatments.

Emergence of CRISPR-Cas9–based Therapy

CRISPR-Cas9 gene editing is a revolutionary genome-editing technology that enables precise and targeted changes to DNA within living cells. Intellia Therapeutics' Nexiguran Ziclumeran is an investigational, in vivo CRISPR-Cas9 gene-editing therapy designed to treat hereditary transthyretin-mediated (hATTR) amyloidosis by directly targeting the root cause of the disease. It uses a guide RNA to direct the Cas9 enzyme to the TTR gene in liver cells, where Cas9 introduces a double-stranded break in the DNA.

Expected Launch of Emerging hATTR Therapies

Several potential therapies are currently under investigation for the treatment of hATTR. The expected introduction of promising candidates such as Nexiguran, Ziclumeran, ALXN2220, Coramitug, and others between 2025 and 2034 is likely to drive a notable transformation in the hATTR market landscape.

Hereditary Transthyretin Amyloidosis Market Analysis

Treatment approaches for hereditary transthyretin-mediated amyloidosis have become increasingly diverse, targeting multiple stages of the disease. Gene-silencing agents, such as eplontersen (WAINUA), patisiran (ONPATTRO), and inotersen (TEGSEDI), act by suppressing TTR mRNA in the liver, thereby reducing the production of both mutant and normal transthyretin proteins and slowing disease progression through lowered circulating TTR levels. TTR stabilizers, including tafamidis (VYNDAQEL/VYNDAMAX), bind to the protein to prevent its misfolding into amyloid fibrils, delaying organ damage, most notably in the heart. 

Although no therapies are currently approved to degrade amyloid fibrils already deposited in tissues, this remains an area of active research, with some agents offering potential indirect benefits. Liver transplantation, once the standard option for removing the primary source of mutant TTR, is now rarely used given the availability of effective drug therapies. A significant innovation is gene editing, highlighted by Nexiguran Ziclumeran, an in vivo CRISPR-Cas9–based therapy that irreversibly disrupts the TTR gene in liver cells, potentially serving as a one-time curative treatment. In addition to these disease-modifying strategies, supportive care and symptom management remain vital, addressing complications such as peripheral neuropathy, autonomic dysfunction, and cardiomyopathy, which drive much of the disease burden and impact quality of life.

To know more about hereditary transthyretin amyloidosis treatment options, visit @ Approved Hereditary Transthyretin Amyloidosis Drugs

Hereditary Transthyretin Amyloidosis Competitive Landscape

Several potential therapies are being investigated for the management of hATTR. The anticipated launch of promising candidates like Nexiguran ziclumeran (Intellia Therapeutics), ALXN2220 (Neurimmune/Alexion Pharmaceuticals), Coramitug (Novo Nordisk), and others during the forecast period (2025–2034) is expected to bring about a significant shift in the market dynamics of hATTR.

Intellia Therapeutics' Nexiguran ziclumeran (nex-z), also known as NTLA-2001, is an investigational in vivo CRISPR gene-editing therapy being developed by Intellia Therapeutics as a potential one-time treatment for transthyretin (ATTR) amyloidosis. The therapy is engineered to silence the TTR gene, responsible for producing the transthyretin (TTR) protein. Development and commercialization are being led by Intellia in partnership with Regeneron, with the program currently advancing through Phase III clinical trials.

Neurimmune/Alexion Pharmaceuticals' ALXN2220 (formerly NI006) is a human monoclonal antibody that selectively binds with high affinity to the pathogenic amyloid form of transthyretin, without affecting its normal physiological state. It is designed to target both wild-type ATTR and mutant forms associated with hereditary ATTR cardiomyopathy (ATTR-CM) and ATTR polyneuropathy.

The anticipated launch of these emerging therapies are poised to transform the hereditary transthyretin amyloidosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the hereditary transthyretin amyloidosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about therapy for hereditary transthyretin amyloidosis @ Hereditary Transthyretin Amyloidosis Clinical Trials 

Recent Developments in the Hereditary Transthyretin Amyloidosis Market

  • In August 2025, Prothena Corporation announced that Novo Nordisk communicated during their second-quarter 2025 results that they expect to advance coramitug, a potential first-in-class amyloid depleter antibody, into a Phase III program for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025.
  • In June 2025, Alnylam Pharmaceuticals announced that the European Commission (EC) had approved an additional indication for AMVUTTRA (vutrisiran), an orphan RNAi therapeutic, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
  • In May 2025, Intellia Therapeutics announced positive two-year follow-up data from the ongoing Phase I trial of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

What is Hereditary Transthyretin Amyloidosis?

Hereditary transthyretin-mediated (hATTR) amyloidosis is a rare genetic disorder that worsens over time, resulting from mutations in the transthyretin (TTR) gene. These mutations cause abnormal folding of the transthyretin protein, which then deposits as amyloid fibrils in different organs and tissues. The buildup most often impacts the peripheral nerves, heart, and, in some cases, the gastrointestinal system. Symptoms can vary but typically include progressive peripheral neuropathy (numbness, tingling, pain), autonomic dysfunction (such as dizziness and digestive problems), and cardiomyopathy (leading to fatigue, shortness of breath, and heart failure). Without treatment, hATTR amyloidosis causes severe organ damage and can be life-threatening.

Hereditary Transthyretin Amyloidosis Epidemiology Segmentation

The hereditary transthyretin amyloidosis epidemiology section provides insights into the historical and current hereditary transthyretin amyloidosis patient pool and forecasted trends for the leading markets. Around 45% of hATTR cases in the US were specific to familial amyloid polyneuropathy (FAP). Hereditary ATTR affects males and females, with no significant gender prevalence; however, a parent-of-origin effect in carriers is hypothesized, as maternal inheritance of the mutation appears to be associated with a higher risk of disease. In contrast, families with late-onset disease exhibit a male predominance.

The hereditary transthyretin amyloidosis market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

  • Total Prevalent Cases of hATTR 
  • Total Diagnosed Prevalent Cases of hATTR 
  • Type-specific Cases of hATTR 
  • Stage-specific cases of hATTR Distribution of FAC patients by NYHA Criteria
  • New York Heart Association (NYHA) Classification of Familial Amyloid Cardiomyopathy (FAC)

Hereditary Transthyretin Amyloidosis Market Report Metrics

Details

Study Period

2020–2034

Hereditary Transthyretin Amyloidosis Market Report Coverage

7MM [The United States, the EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan].

Hereditary Transthyretin Amyloidosis Epidemiology Segmentation

Total Prevalent Cases of hATTR, Total Diagnosed Prevalent Cases of hATTR, Type-specific Cases of hATTR, Stage-specific cases of hATTR Distribution of FAC patients by NYHA Criteria, and New York Heart Association (NYHA) Classification of Familial Amyloid Cardiomyopathy (FAC)

Key Hereditary Transthyretin Amyloidosis Companies

Intellia Therapeutics, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Alnylam Pharmaceuticals, AstraZeneca, Ionis Pharmaceuticals, and others

Key Hereditary Transthyretin Amyloidosis Therapies

Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, AMVUTTRA, WAINUA, ONPATTRO, TEGSEDI, and others

Scope of the Hereditary Transthyretin Amyloidosis  Market Report

  • Therapeutic Assessment: Hereditary Transthyretin Amyloidosis current marketed and emerging therapies
  • Hereditary Transthyretin Amyloidosis Market Dynamics: Key Market Forecast Assumptions of Emerging Hereditary Transthyretin Amyloidosis Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Hereditary Transthyretin Amyloidosis Market Access and Reimbursement

Download the report to understand which factors are driving hereditary transthyretin amyloidosis therapeutics market trends @ Hereditary Transthyretin Amyloidosis Market Trends

Table of Contents

1

Hereditary Transthyretin Amyloidosis Market Key Insights

2

Hereditary Transthyretin Amyloidosis Market Report Introduction

3

Executive Summary

4

Key Events

4.1

Key Transactions and Collaborations

5

Epidemiology and Market Forecast Methodology of hATTR

6

hATTR Market Overview at a Glance

6.1

Hereditary Transthyretin Amyloidosis Market Landscape Analysis (By Phase, RoA, and Molecule type)

6.2

Emerging Landscape Analysis (By Phase, RoA, and Molecule type)

6.3

Market Share (%) Distribution of hATTR by Therapies in 2024

6.4

Market Share (%) Distribution of hATTR by Therapies in 2034

7

Disease Background and Overview

7.1

Hereditary Transthyretin Amyloidosis Introduction

7.2

Hereditary Transthyretin Amyloidosis Signs and Symptoms 

7.3

Hereditary Transthyretin Amyloidosis Types

7.4

Hereditary Transthyretin Amyloidosis Classification

7.5

Hereditary Transthyretin Amyloidosis Causes

7.6

Hereditary Transthyretin Amyloidosis Stages

7.7

Hereditary Transthyretin Amyloidosis Diagnosis

8

Hereditary Transthyretin Amyloidosis Treatment

9

Epidemiology and Patient Population of hATTR

9.1

Key Findings

9.2

Assumptions and Rationale

9.3

Total Prevalent Cases of hATTR in the US

9.4

The United States

9.4.1

Total Prevalent Cases of Hereditary Transthyretin Amyloidosis (hATTR) 

9.4.2

Total Diagnosed Prevalent Cases of Hereditary Transthyretin Amyloidosis (hATTR) 

9.4.3

Type-specific Cases of Hereditary Transthyretin Amyloidosis (hATTR)

9.4.4

Stage-specific Cases of Hereditary Transthyretin Amyloidosis (hATTR)

9.4.5

New York Heart Association (NYHA) Classification of Familial Amyloid Cardiomyopathy (FAC)

9.5

EU4 and the UK

9.6

Japan

10

Patient Journey of hATTR

11

Marketed Therapies of hATTR

11.1

Key Competitors

11.2

AMVUTTRA (vutrisiran): Alnylam Pharmaceuticals

11.2.1

Product Description

11.2.2

Regulatory Milestone

11.2.3

Other Development Activities

11.2.4

Summary of Pivotal Trials

11.2.5

Clinical Trials Information

11.2.6

Analyst Views

11.3

WAINUA (eplontersen): AstraZeneca/Ionis Pharmaceuticals

List to be continued in the report…

12

Emerging Therapy of hATTR

12.1

Key Competitors

12.2

Nexiguran Ziclumeran: Intellia Therapeutics

12.2.1

Product Description

12.2.2

Other Development Activities

12.2.3

Clinical Development

12.2.3.1

Clinical Trials Information

12.2.4

Safety and Efficacy

12.2.5

Analyst Views

List to be continued in the report…

13

hATTR Market: Seven Major Market Analysis

13.1

Key Findings

13.2

Hereditary Transthyretin Amyloidosis Market Outlook

13.3

Key Hereditary Transthyretin Amyloidosis Market Forecast Assumptions

13.4

Conjoint Analysis

13.5

Launch Year and Therapy Uptakes

13.6

Total Market Size of  hATTR in the 7MM

13.7

Market Size of hATTR by Therapies in the 7MM

13.8

The United States Hereditary Transthyretin Amyloidosis Market Size

13.8.1

Total Market Size of hATTR in the United States

13.8.2

Market Size of hATTR by Therapies in the United States

13.9

EU4 and the UK Hereditary Transthyretin Amyloidosis Market Size

13.10

Japan Hereditary Transthyretin Amyloidosis Market Size

14

Unmet Needs of hATTR

15

SWOT Analysis of hATTR

16

KOL Views of hATTR

17

Hereditary Transthyretin Amyloidosis Market Access and Reimbursement

18

Bibliography

19

Hereditary Transthyretin Amyloidosis Market Report Methodology

Related Reports

Hereditary Transthyretin Amyloidosis Clinical Trial Analysis 

Hereditary Transthyretin Amyloidosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hATTR companies, including Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, Intellia Therapeutics, Corino Therapeutics, Novo Nordisk, among others.

Transthyretin Amyloidosis Market

Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key transthyretin amyloidosis companies, including Alnylam Pharmaceutical, Ionis Pharmaceuticals, Akcea, Eidos Therapeutics, Intellia, Regeneron, among others.

Transthyretin Amyloid Cardiomyopathy Market

Transthyretin Amyloid Cardiomyopathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ATTR-CM companies, including Intellia Therapeutics, YolTech Therapeutics Co., Ltd, Alexion Pharmaceuticals, Inc., among others.

Transthyretin Amyloid Cardiomyopathy Clinical Trial Analysis

Transthyretin Amyloid Cardiomyopathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ATTR-CM companies, including Intellia Therapeutics, YolTech Therapeutics Co., Ltd, Alexion Pharmaceuticals, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight

AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight

DelveInsight's AHR Agonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of...

Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight

Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Lupus Nephritis Market Insights report includes a comprehensive understanding of current treatment practices, lupus nephritis emerging ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • PR Newswire Amplify™
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.